Patents by Inventor Robert Ian Dowell

Robert Ian Dowell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Metalloproteinase inhibitor compounds
    Patent number: 7122551
    Abstract: Compounds of the formula I useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: October 17, 2006
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Robert Ian Dowell, Maurice Raymond Verschoyle Finlay, Nicholas John Newcombe, Howard Tucker, David Waterson
  • Chemical compounds
    Patent number: 6436691
    Abstract: Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems for use in cancer based on mutated carboxypeptidase B (CPB) enzymes. Enzyme conjugates for ADEPT are substantially non-immunogenic in humans comprising a targeting moiety (for example an antibody) capable of binding with a tumor associated antigen, the targeting moiety being linked to a mutated form of a CPB enzyme capable of converting a prodrug into an antineoplastic drug wherein the prodrug is not significantly convertible into antineoplastic drug in humans by natural unmutated enzyme. A preferred enzyme mutant is human pancreatic CPB comprising a Lys or Arg residue at position 253. Suitable mustard prodrugs are disclosed in the specification.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: August 20, 2002
    Assignee: Zeneca Limited
    Inventors: Anthony Michael Slater, David Charles Blakey, David Huw Davies, John Frederick Hennam, Laurent Francois Andre Hennequin, Peter Robert Marsham, Robert Ian Dowell
  • Chemical compounds
    Patent number: 6277880
    Abstract: Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalysed reactions.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: August 21, 2001
    Assignees: Zeneca Limited, Cancer Research Campaign Technology Limited
    Inventors: Philip John Burke, Robert Ian Dowell, Anthony Brian Mauger, Caroline Joy Springer
  • High purity N-(4-[N,N-bis(2-iodoethyl)amino]phenoscycarbonyl)-L-glutamic acid
    Patent number: 5981791
    Abstract: A new salt of a prodrug useful in antibody directed enzyme prodrug therapy (ADEPT) is disclosed. A hydrogen iodide salt of the prodrug N-(4-[N,N-bis(2-iodoethyl)amino]phenoxycarbonyl)-L-glutamic acid is prepared which can be obtained in crystalline form. Preparation of the crystalline form of the prodrug enables preparation of the prodrug in highly pure form.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: November 9, 1999
    Assignee: Zeneca Limited
    Inventors: David William Heaton, Susan Dines, Robert Ian Dowell
  • Chemical compounds
    Patent number: 5958971
    Abstract: Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalyzed reactions.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: September 28, 1999
    Assignees: Zeneca Limited, Cancer Research Campaign Technology Limited
    Inventors: Philip John Burke, Robert Ian Dowell, Anthony Brian Mauger, Caroline Joy Springer
  • Chemical compounds
    Patent number: 5714148
    Abstract: Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalysed reactions.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: February 3, 1998
    Assignees: Zeneca Limited, Cancer Research Campaign Technology Limited
    Inventors: Philip John Burke, Robert Ian Dowell, Anthony Brian Mauger, Caroline Joy Springer
  • Process for antibody directed enzyme prodrug therapy
    Patent number: 5660829
    Abstract: Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalysed reactions.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: August 26, 1997
    Assignees: Zeneca Limited, Cancer Research Campaign Technology
    Inventors: Philip John Burke, Robert Ian Dowell, Anthony Brian Mauger